EUVIMEDEUVIMED entdecken
Open Access

Durvalumab-induced triple-M syndrome

Femi Williams Adeoye, Nida Jaffar, Sanggeeta Surandran, Gulshad Begum, Mohammad Rafiqul Islam

European Journal of Case Reports in Internal Medicine · 30.07.2024 · 11 (8)

DOI: 10.12890/2024_004729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Case Reports in Internal Medicine, online erschienen am 30.07.2024. Verfasst von Femi Williams Adeoye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Southend University Hospital, Southend-on-Sea, United Kingdom. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While the use of immunotherapy has revolutionised the treatment of various cancers, it is often associated with a myriad of immune-related adverse effects. Case Presentation: In this article, we report a rare case of durvalumab-induced triple-M syndrome in a 69-year-old woman with stage III lung adenocarcinoma. She was admitted with profound generalised muscle weakness, myalgia, and exertional breathlessness, about a week into her second cycle of durvalumab, an immune checkpoint inhibitor. She had clinicopathological features of myositis, myasthenia and myocarditis with acute onset symptomatic tri-fascicular block on electrocardiogram, requiring urgent cardiology intervention. Durvalumab was discontinued and she was treated with a combination of high-dose steroids and intravenous immunoglobulin after which she had clinical and biochemical improvement, albeit with residual muscle weakness.

Conclusion

Myocarditis-myositis-myasthenia complex is a rare side effect of immunotherapy which has been reported in other immune checkpoint inhibitors, but less so with durvalumab. We report this clinical case to raise awareness of this rare and potentially life-threatening adverse effect of this agent.

Schlagwörter

Stichwörter der Autor:innen

Durvalumabmyastheniammyocarditismyositistriple-M syndrome

Autor:innen und Institutionen

  • Southend University Hospital, Southend-on-Sea, United Kingdom.
  • Oncology Department, Southend University Hospital, Southend-on-Sea, United Kingdom.
  • Internal Medicine Department, Basildon University Hospital, Basildon, United Kingdom.
  • Mid and South Essex NHS Foundation Trust, Essex, United Kingdom.

Zitieren

APA

Adeoye, F. W., Jaffar, N., Surandran, S., Begum, G., & Islam, M. R. (2024). Durvalumab-induced triple-M syndrome. European Journal of Case Reports in Internal Medicine, 11(8). https://doi.org/10.12890/2024_004729

Vancouver

Adeoye FW, Jaffar N, Surandran S, Begum G, Islam MR. Durvalumab-induced triple-M syndrome. European Journal of Case Reports in Internal Medicine. 2024;11(8). doi:10.12890/2024_004729

BibTeX
@article{Adeoye2024,
  author = {Adeoye, Femi Williams and Jaffar, Nida and Surandran, Sanggeeta and Begum, Gulshad and Islam, Mohammad Rafiqul},
  title = {Durvalumab-induced triple-M syndrome},
  journal = {European Journal of Case Reports in Internal Medicine},
  year = {2024},
  volume = {11},
  number = {8},
  doi = {10.12890/2024_004729}
}
Kostenlos starten →